Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 01, 2021

SELL
$282.99 - $369.05 $175,453 - $228,811
-620 Closed
0 $0
Q2 2021

Aug 02, 2021

BUY
$259.0 - $414.71 $160,580 - $257,120
620 New
620 $215,000
Q4 2020

Feb 02, 2021

SELL
$236.26 - $355.63 $172,469 - $259,609
-730 Closed
0 $0
Q3 2020

Nov 06, 2020

BUY
$264.77 - $305.71 $193,282 - $223,168
730 New
730 $207,000
Q2 2020

Aug 04, 2020

SELL
$258.66 - $342.55 $257,366 - $340,837
-995 Closed
0 $0
Q4 2019

Feb 06, 2020

BUY
$220.06 - $304.07 $25,526 - $35,272
116 Added 13.2%
995 $295,000
Q2 2019

Aug 09, 2019

SELL
$219.29 - $241.72 $438 - $483
-2 Reduced 0.23%
879 $206,000
Q1 2019

May 21, 2019

SELL
$216.71 - $338.96 $19,287 - $30,167
-89 Reduced 9.18%
881 $208,000
Q1 2019

May 14, 2019

BUY
$216.71 - $338.96 $17,986 - $28,133
83 Added 9.36%
970 $229,000
Q4 2018

Feb 14, 2019

BUY
$278.5 - $352.75 $247,029 - $312,889
887 New
887 $267,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Gyl Financial Synergies, LLC Portfolio

Follow Gyl Financial Synergies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gyl Financial Synergies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gyl Financial Synergies, LLC with notifications on news.